Clinical Trials Logo

Clinical Trial Summary

The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.


Clinical Trial Description

Background: The standard of care for potentially premalignant oral epithelial lesion (PPOEL) risk assessment for progression to cancer is dysplasia grading by histopathology. With significant overlap between dysplasia grades and high inter- and intra-observer variations, dysplasia grading alone has been shown to be inadequate as a prognostic tool. To investigate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in the early diagnosis of invasive oral cancer, a prospective multi-center observational study was designed with specimens obtained from community-based practices. Methods: Patients that qualify to enroll in the study will be assessed for both standard of care histopathological assessment for dysplasia grade and STRATICYTE risk assessment, and followed for up to 60 months (from initial biopsy) to determine the outcome of their oral lesion(s). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04622462
Study type Observational
Source Proteocyte Diagnostics Inc.
Contact Jason Hwang, PhD
Phone (647) 255-1370
Email jhwang@proteocyte.com
Status Recruiting
Phase
Start date March 12, 2015
Completion date December 31, 2026

See also
  Status Clinical Trial Phase
Completed NCT03653039 - Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy N/A
Recruiting NCT03942380 - Cell-free Tumor DNA in Head and Neck Cancer Patients N/A
Active, not recruiting NCT00542373 - Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer N/A